BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15447757)

  • 1. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
    Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
    Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S; Papa A
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants.
    Saibeni S; Cattaneo M; Vecchi M; Zighetti ML; Lecchi A; Lombardi R; Meucci G; Spina L; de Franchis R
    Am J Gastroenterol; 2003 Jan; 98(1):112-7. PubMed ID: 12526945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
    Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
    Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
    Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N; Guldiken S; Demir M; Tugrul A
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia.
    Spina L; Saibeni S; Battaglioli T; Peyvandi F; de Franchis R; Vecchi M
    Am J Gastroenterol; 2005 Sep; 100(9):2036-41. PubMed ID: 16128949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhomocysteinemia in inflammatory bowel disease patients without past intestinal resections: correlations with cobalamin, pyridoxine, folate concentrations, acute phase reactants, disease activity, and prior thromboembolic complications.
    Erzin Y; Uzun H; Celik AF; Aydin S; Dirican A; Uzunismail H
    J Clin Gastroenterol; 2008; 42(5):481-6. PubMed ID: 18344891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased thrombin generation in inflammatory bowel diseases.
    Saibeni S; Saladino V; Chantarangkul V; Villa F; Bruno S; Vecchi M; de Franchis R; Sei C; Tripodi A
    Thromb Res; 2010 Mar; 125(3):278-82. PubMed ID: 19914688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
    Chen CC; Lee KD; Gau JP; Yu YB; You JY; Lee SC; Hsu HC; Chau WK; Ho CH
    Ann Hematol; 2005 Oct; 84(10):675-80. PubMed ID: 16007424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
    Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
    Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
    Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
    Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
    Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis.
    Shen J; Ran ZH; Zhang Y; Cai Q; Yin HM; Zhou XT; Xiao SD
    Thromb Res; 2009 Feb; 123(4):604-11. PubMed ID: 18499234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
    Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
    Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
    Guven GS; Kiliçaslan A; Oz SG; Haznedaroglu IC; Kirazli S; Aslan D; Sözen T
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):364-8. PubMed ID: 16959692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.